February 24th, 2015

Working to Redefine Healthcare: FORTUNE Magazine Names Johnson & Johnson #1 in Pharmaceuticals

By Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson and Joaquin Duato, Worldwide Chairman, Janssen Pharmaceutical Companies of Johnson & Johnson

We are honored that for the second consecutive year FORTUNE Magazine ranked Johnson & Johnson and its Janssen Pharmaceutical Companies #1 in the Pharmaceuticals category on its annual World’s Most Admired Companies list. It is a reflection of the hard work, passion and dedication of our Janssen team, and a testament to our commitment to improve people’s lives around the world.

At Janssen, what matters most is a healthy outcome for every patient and this cannot be achieved by simply making incremental improvements to healthcare. We must continue to be bold, collaborative and innovative. Here are some examples of progress we’ve made over the past year:

  • Our efforts to combat Ebola, in partnership with Bavarian Nordic and consortia of leading global research institutions and NGOs reflect our commitment to global public health;
  • Agreements with organizations like Stop TB Partnership’s Global Drug Facility are helping to expand access to our medicines;
  • Through the Johnson & Johnson Innovation Centers‒JLabs, we are expanding our reach, identifying the best science and partners in life science hot spots around the globe; and
  • New recently-launched research platforms — the Janssen Prevention Center, the Disease Interception Accelerator, and the Janssen Human Microbiome Institute —  focus in three areas of transformational medical innovation that are expected to change the global healthcare landscape.

Read More

February 23rd, 2015

Welcome to J&J News Center 2.0

By Maggie FitzPatrick, Chief Communication Officer, Johnson & Johnson

We are pleased today to unveil our redesigned J&J News Center, a digital storytelling hub on JNJ.com that gives you a front-row view of the work that our 130,000 employees do every day to serve more than one billion people throughout the world.

Our News Center

The new site will serve as an invaluable content resource, allowing Johnson & Johnson to more fully and immediately engage with our stakeholders about breaking news and our stories of caring, science, public health and innovation.

From our new Ebola page, where we share the latest news about our efforts to fast-track our vaccine program, to the new Thought Leaders section featuring expert voices from across Johnson & Johnson, the News Center will be a dynamic resource to help you stay informed about important health care issues and learn what’s going on behind the scenes at J&J.

Johnson & Johnson Thought Leaders

To get a snapshot of what’s happening around J&J in real-time, I invite you to also visit our newly expanded Follow Us page where the latest conversations are taking place about innovation, public health, parenting and more.

Johnson & Johnson - Follow Us

Across Johnson & Johnson, we are on a journey to continually strengthen engagement and trust with each of you.

Read More

February 12th, 2015

Launching New Research Platforms

By William N. Hait, Global Head, Research & Development, Janssen, Pharmaceutical Companies of Johnson & Johnson

Bill Hait Quote

As a father, physician, scientist and leader of a global R&D organization, I care deeply about the future of health care.

Today, we focus much of our effort on treating established disease rather than placing the majority of our resources behind preventing. Someday, the next generations will look back on us and say, “Can you believe it, they actually waited until they had a disease before doing something about it!”

In my opinion, the future of health care will increasingly depend on identifying and correctly interpreting the susceptibility to disease, on accurately measuring risk, then on preventing or intercepting disease before its onset. Then, by deploying the latest scientific insights from promising, emerging fields, we shall transform the practice of medicine.

Over the past 100 years, preventive measures such as improved hygiene and vaccines have greatly reduced the impact of infectious diseases. However, the impact of chronic non-communicable diseases like Alzheimer’s disease, various cancers, cardiovascular disease and diabetes is steadily increasing in most parts of the world.

Health care costs continue to rise, and payers are struggling to fund the growing needs of aging demographics.

Read More

February 10th, 2015

Staying Resolute in New Year’s Resolutions

By Chris Jordan, Director of Exercise Physiology, Human Performance Institute Division of Wellness and Prevention, Inc., a Johnson & Johnson company

We are just over a month into 2015, so how are your New Year’s Resolutions going? Many of us take a good look at ourselves at the end of each year and decide to embark on an overly optimistic exercise plan for the New Year with good intentions of losing weight and improving our health and fitness. Perhaps we even set goals such as getting in shape for the summer and looking good on the beach.

Chris-Jordan - Stay Motivated

We have all seen how busy the fitness centers are in January. It can be hard to get on our preferred cardio machine or get a spot in our favorite workout class. Like all New Year’s resolutions, the exercise resolution often starts well. We get up early every morning for a run or we make it to the gym every evening after work. We may even add a workout in during the weekend! And, we feel good. Not just physically (we know exercise can boost our energy levels), but also emotionally and mentally, partly because we did what we committed to do. We feel we accomplished something and we are on track with our plan for the New Year!

Read More

February 5th, 2015

Making Every Moment Matter

by Tara Glasgow, Vice President of Research & Development, Global Baby

Making Every Moment Matter

As a mom, I understand the need for other moms and dads to treasure the precious moments throughout the day we get to spend with our children. From bath time to bedtime, all of these moments turn into our very own special rituals and serve as a way to bond and develop a relationship with our little ones. What may come as a surprise to some is how all of these everyday interactions serve as the perfect opportunity to stimulate your baby’s senses, which we believe can have a positive impact on their development.

Working on JOHNSON’S®, I’ve had the chance to meet parents all over the world and look at the unique rituals and practices between them and their baby. What I found to be universal is the desire for families to raise happy, healthy babies.

As the first baby care brand to commit to advancing the science of baby’s skin, we feel, as scientists, an obligation to continue to take our research to the next level by looking at all the science— even beyond the science focused on cleansing— that help our babies thrive and grow. It’s why I am so excited about the new and existing research we are sharing that reveals the importance of multi-sensorial experiences that can lead to happy, healthy baby development.

Read More

January 29th, 2015

Working together to tackle vaccine preventable disease in children

by Johan Van Hoof, M.D., Global Therapeutic Area Head Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson, and Managing Director, Crucell Holland B.V.

GAVI

This week in Berlin, Gavi, The Vaccine Alliance, an organization which improves access to new and underused vaccines for children, brought together world leaders and stakeholders to welcome new commitments towards its mission to immunize children in developing countries. I am proud to say that Janssen, the pharmaceutical companies of Johnson & Johnson, were a part of this group which pledged a total of US$7.5 billion, which will enable countries to immunize an additional 300 million children.

I would personally like to congratulate the world community and Gavi on this renewed commitment and pledge which is expected to help save an estimated five to six million lives by 2020. In the 15 years since the international organization Gavi was founded, half a billion children have already received lifesaving vaccines through their work.

As a parent myself, I believe the dramatic decline in preventable child deaths during the past 25 years is one of humankind’s greatest achievements. Deadly and debilitating diseases are entirely preventable through immunization and by investing in vaccines, we can do far more than protect health; we can also protect people’s incomes and savings, and promote economic growth.

Read More

January 20th, 2015

WW Pharmaceuticals Chairman Joaquin Duato Shares His Leadership Perspectives in PwC’s 18th Annual Global CEO Survey

Joaquin Duato CEO Survey

Editor’s Note:  Joaquin Duato, Worldwide Chairman of our Janssen Pharmaceutical Companies, was asked to participate in the 18th Annual PricewaterhouseCoopers (PwC) LLC Global CEO Survey on behalf of Johnson & Johnson and our senior leadership team. Every year, PwC interviews top global leaders about the global economy and their perspectives on business challenges and opportunities.

This year’s survey focuses on themes such as strategies for business growth, the emergence of digital technology, and talent diversity and adaptability.  The survey results were shared earlier today in Davos, Switzerland on the eve of the Annual Meeting of the World Economic Forum.

We invite you to watch the PwC interview and hear Joaquin’s perspectives on topics including accelerating medical innovation, tech and big data development and addressing global threats such as the Ebola health crisis.

Learn more about Joaquin’s leadership role at Johnson & Johnson by visiting his senior management page bio.

Read More

January 14th, 2015

A new culture in science, a better outcome for public health

By Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson

Innovation in the interest of public health happens faster when researchers in both the public and private sectors share information and work together. We’ve seen this happening to the greatest extent during the current Ebola epidemic. Imagine if this were the new culture and the new standard in science.  If done responsibly so that we could also maintain a healthy R&D ecosystem, sharing data from clinical studies can help advance the science that is the foundation of all medical care.

Our primary responsibility, as one of the most broadly based healthcare companies in the world, is to the doctors and nurses, patients and consumers, mothers, fathers and children who use our products. That means taking a patient and consumer-centered approach to advancing medical science through all of our products that touch people in different ways. It also means we have the opportunity to set the standard and be leaders and role models in advancing best practices that will ultimately advance science and medicine.

When we announced early last year that we would partner with the Yale School of Medicine Open Data Access Project (YODA) to serve as an independent reviewer for every request for clinical data from our pharmaceutical studies, we broke new ground in data transparency.

Read More

January 6th, 2015

Collaborating to Speed Development of an Ebola Vaccine

By Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Ebola continues to cause suffering among patients, families and health care workers in West Africa.  In response, the world’s scientific, pharmaceutical, regulatory, and public health communities have united in taking action to find new ways to collaborate and drive forward innovations to help prevent Ebola infection.  These collaborative efforts are happening at record pace, and they offer a window into what is possible in the face of a global epidemic.

Speed matters.  To date, almost 8,000 people have died from Ebola and more than 20,000 cases have been reported and the numbers continue to rise.

This sense of urgency has motivated our teams to work day and night in our labs and in close collaboration with partners such as the World Health Organization, U.S. Centers for Disease Control and Prevention, UK Medicines and Healthcare Products Regulatory Agency on finding a solution as fast as possible. Together we are working to accelerate the process of developing, producing and distributing a preventive Ebola vaccine regimen.

As a result of these collaborative efforts, today Johnson & Johnson announced the start of a Phase 1 first-in-human clinical trial of a preventive Ebola vaccine regimen in development at our Janssen Pharmaceutical Companies.

Read More

December 27th, 2014

The 10 Most-read Stories of 2014

Compiled by the Johnson & Johnson Social Media Team

From paying tribute to our military veterans to the continued fight against HIV and AIDS, Johnson & Johnson had a wealth of stories and news to share on a wide range of topics in 2014. Here’s a list of the top 10 JNJ Blog posts that readers clicked on the most. Visit us here in 2015 when we continue the conversation about J&J news and events.

10. Meet Our U.S. Military Veterans

In honor of Veterans Day this year, J&J recognized and thanked all those who served in the military, including our own employees. This post featured 27 employees who are veterans and work across our Pharmaceutical, Medical Devices & Diagnostics and Consumer segments.

9. Healthy Minds Program Explores Major Depressive Disorder

Across the globe, approximately 450 million people suffer from a mental or neurological disorder, yet nearly 60 percent who have a known disorder never consult a doctor to better understand their mental health.

Read More